C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten by Stopford, Matthew J et al.
O R I G I N A L A R T I C L E
C9ORF72 hexanucleotide repeat exerts toxicity in a
stable, inducible motor neuronal cell model, which is
rescued by partial depletion of Pten
Matthew J. Stopford1, Adrian Higginbottom1, Guillaume M. Hautbergue1,
Johnathan Cooper-Knock1, Padraig J. Mulcahy1, Kurt J. De Vos1,
Alan E. Renton2, Hannah Pliner2, Andrea Calvo3, Adriano Chio3,
Bryan J. Traynor2, Mimoun Azzouz1, Paul R. Heath1, ITALSGEN Consortium,
NeuroX Consortium, Janine Kirby1 and Pamela J. Shaw1,*
1Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield,
Sheffield S10 2HQ, UK, 2Neuromuscular Diseases Research Section, National Institute on Aging, National
Institutes of Health, Bethesda, MD 20892, USA and 3Department of Neuroscience, University of Turin,
Turin, Italy
*To whom correspondence should be addressed at: Tel: þ44 1142222295; Fax: þ44 1142222290; Email: pamela.shaw@sheffield.ac.uk
Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating and incurable neurodegenerative disease, characterised by progressive
failure of the neuromuscular system. A (G4C2)n repeat expansion in C9ORF72 is the most common genetic cause of ALS and
frontotemporal dementia (FTD). To date, the balance of evidence indicates that the (G4C2)n repeat causes toxicity and
neurodegeneration via a gain-of-toxic function mechanism; either through direct RNA toxicity or through the production of
toxic aggregating dipeptide repeat proteins. Here, we have generated a stable and isogenic motor neuronal NSC34 cell model
with inducible expression of a (G4C2)102 repeat, to investigate the gain-of-toxic function mechanisms. The expression of the
(G4C2)102 repeat produces RNA foci and also undergoes RAN translation. In addition, the expression of the (G4C2)102 repeat
shows cellular toxicity. Through comparison of transcriptomic data from the cellular model with laser-captured spinal motor
neurons from C9ORF72-ALS cases, we also demonstrate that the PI3K/Akt cell survival signalling pathway is dysregulated in
both systems. Furthermore, partial knockdown of Pten rescues the toxicity observed in the NSC34 (G4C2)102 cellular gain-of-
toxic function model of C9ORF72-ALS. Our data indicate that PTEN may provide a potential therapeutic target to ameliorate
toxic effects of the (G4C2)n repeat.
Introduction
A (G4C2)n repeat expansion in a non-coding region of the
C9ORF72 gene has been established as the most common
identified genetic cause of amyotrophic lateral sclerosis (ALS) as
well as frontotemporal dementia (FTD) (1,2). Expansions of >30
repeats are considered pathogenic (3,4), but expansions of 200–
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5000 repeats are more commonly detected in ALS patients (5). The
mechanism(s) by which the repeat causes neuronal death in the
motor cortex, brainstem and spinal cord in ALS and/or neuronal
death in the frontal and temporal lobes of the brain in FTD are cur-
rently being elucidated, with three hypotheses proposed which
are not mutually exclusive: (1) Haploinsufficiency of C9ORF72; (2)
RNA toxicity; and (3) Dipeptide repeat protein (DPR) toxicity.
Various reports demonstrate C9ORF72 mRNA is reduced in
post-mortem CNS tissue, lymphoblast cells and iPSC-derived neu-
rons of patients containing the (G4C2)n repeat expansion (1,6–10)
and that C9ORF72 protein is also reduced in the frontal cortex of
patients with the repeat expansion (10,11), suggesting C9ORF72
haploinsufficiency as a potential pathogenic mechanism. In add-
ition, knockdown or deletion of C9ORF72 orthologues in zebrafish
and Caenorhabditis Elegans, respectively, caused motor dysfunction
(7,12). C9ORF72 protein regulates autophagy induction and auto-
phagic flux, and both C9ORF72-ALS/FTD derived neurons and
mice lacking functional C9ORF72 protein have impaired autoph-
agy (13–15). However, mice lacking functional C9ORF72 do not
show signs of neurodegeneration or reduced motor function, al-
though they do display autoimmunity and other immune system
dysregulation (13,16–19). Equally, when C9ORF72 knockdown (ei-
ther partial or complete) was confined to the CNS in adult mice,
there were no behavioural or motor defects, nor any signs of
neuropathology associated with ALS and FTD (20,21).
The (G4C2)n repeat expansion is also suggested to exert a
toxic gain-of-function via either direct RNA toxicity and/or DPR
proteins. The (G4C2)n repeat is transcribed in both sense and
antisense directions, and forms sense (G4C2)n and antisense
(C4G2)n RNA foci, respectively. These RNA foci are present in
C9ORF72-ALS/FTD CNS tissue and neuronal cells (1,22), and may
potentially sequester essential RNA binding proteins leading to
dysregulated RNA processing, as seen in other repeat expansion
disorders (23). Several RNA binding proteins bind (G4C2)n and/
or (C4G2)n RNA in vitro, and also colocalise with RNA foci in pa-
tient CNS tissue (9,24–29). In addition, transcriptomic analysis
of C9ORF72-ALS/FTD patient CNS tissue showed dysregulation
in RNA splicing and processing (30,31).
The (G4C2)n repeat also undergoes unconventional repeat
associated non-ATG (RAN) translation in all reading frames in
both the sense and antisense directions, forming aggregation-
prone DPR proteins (32,33). The five species of DPR proteins
(poly-GA, poly-GR, poly-GP, poly-AP and poly-PR) produced
form insoluble inclusions in C9ORF72-ALS/FTD patient CNS tis-
sue (32–35). DPR proteins are toxic in cultured cells and cause
neurodegeneration in Drosophila models (35–42). The arginine-
rich DPR proteins (poly-GR and poly-PR) appear particularly
toxic, localise to the nucleolus, disrupt ribosomal RNA biogen-
esis and cause cell death (36–39,41). Also, in two elegant studies
using Drosophila models, the toxicity of (G4C2)n repeats was de-
pendent on the production of DPR, and not (G4C2)n RNA foci
(41,43). However, while these studies suggest that the DPR are
the likely major toxic insult derived from the sense (G4C2)n
RNA, antisense (C4G2)n RNA foci, but not sense (G4C2)n RNA
foci, correlate with TDP-43 proteinopathy in motor neurons
from C9ORF72-ALS patients (44). Furthermore in C9ORF72-ALS
patients, DPR load is much lower in spinal motor neurons com-
pared with other unaffected regions of CNS, and TDP-43 inclu-
sions rarely co-localise with DPR suggesting that they may not
be the primary toxic insult in motor neuron degeneration
(45–48).
Several recently generated mouse models of C9ORF72-ALS
have produced fairly variable results. In one study, a (G4C2)66
construct was delivered to the CNS of the mice and resulted in
RNA foci, DPR, and TDP-43 pathology, as well as behavioural
and motor defects (49). In two other studies, C9ORF72 BAC
transgenic mouse models were generated that contain the
(G4C2)n repeat expansion within either part of or all of the
C9ORF72 gene and display both the RNA foci and DPRs, yet sur-
prisingly did not develop signs of neurodegeneration or ALS/
FTD phenotypes (50,51). Another group described similar find-
ings in different C9ORF72 BAC lines, with the addition of a cog-
nitive phenotype (52). However, in a fourth C9ORF72 BAC mouse
model, there was TDP-43 pathology, motor neuron degeneration
and a neurodegenerative phenotype, including weakness,
weight loss, breathing problems and decreased survival, as well
as anxiety-like behaviour (53). While these studies are incon-
sistent in their findings, they demonstrate that (G4C2)n repeat
length and expression level, as well as other contributing gen-
etic factors may contribute to ALS pathogenesis.
In further support of a gain-of-toxic function, ASOs that tar-
get sense C9ORF72 transcripts not only reduce (G4C2)n RNA foci
number, they also ameliorate transcriptomic changes and re-
duce toxicity in iPSC-derived neuronal cells from C9ORF72-ALS/
FTD patients (9,20,27). The balance of evidence is emerging that
a gain-of-toxic function is more likely than C9ORF72 haploinsuf-
ficiency to provide the major toxic insult that drives C9ORF72-
ALS and/or FTD. However, the relative contributions of the
sense and antisense RNA, and each of the DPR species in the
neuronal injury of C9ORF72-ALS and FTD have not been fully es-
tablished. In addition, a loss of C9ORF72 function may still ex-
acerbate the primary toxic insult, contributing to ALS/FTD
pathogenesis. Therefore, we aimed to generate a gain-of-toxic
function model to identify potential therapeutic targets for
C9ORF72-ALS. We generated a stable motor neuron-like cell
model with inducible (G4C2)n expression, which allowed identi-
fication of the early biochemical changes associated with the
expression of the (G4C2)n repeat expansion. Our results showed
that (G4C2)102 constructs produced RNA foci, underwent RAN
translation and caused toxicity in NSC34 cells. Transcriptomic
analysis of the NSC34 cell model identified dysregulation in the
PI3K/Akt signalling pathway, which was validated in motor neu-
rons from C9ORF72-ALS patients. Further, we showed that par-
tial knockdown of Pten, the normal function of which is to
negatively regulate the PI3kinase/Akt cell survival pathway,
provided a rescue effect in the NSC34 cell model, suggesting
that PTEN could represent a potential therapeutic target for
C9ORF72-ALS.
Results
Generation of stable NSC34 cell models with
tetracycline-inducible (G4C2)n expression
The primary aim of this work was to establish the gain-of-
function effects from the (G4C2)n repeat expansion independ-
ent of the C9ORF72 gene context, and thereby identify potential
therapeutic targets for C9ORF72-ALS. To address this, we gener-
ated stable, isogenic motor neuronal NSC34 cell models with
tetracycline-inducible expression of 0 (sham) or 102 (G4C2)n re-
peats. First, (G4C2)10 repeat constructs were synthesised, and
subsequently used to generate interrupted (G4C2)n repeat con-
structs containing 102 repeats (Fig. 1A). These (G4C2)102 con-
structs were then sub-cloned into pcDNA5/FRT/TO plasmids
(Invitrogen) that contain an FRT site and a CMV/tetracycline op-
erator hybrid promoter (Fig. 1B). The pcDNA5/FRT/TO-(G4C2)102
vectors were then stably integrated into Flp-InTM T-RExTM
NSC34 cells (that were generated in house). In addition, empty
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pcDNA5/FRT/TO vectors were integrated into Flp-InTM T-RExTM
NSC34 cells, generating NSC34 sham as a control in vitro model.
The interrupted (G4C2)n repeat RNA forms characteristic
RNA foci comparable to those detectable in the CNS of
C9ORF72-ALS cases. Therefore, RNA fluorescence in situ hybrid-
isation (FISH) was used to detect expression of the (G4C2)n RNA
in the NSC34 (G4C2)102 cells. The number of sense (G4C2)n RNA
foci increased when the cells were induced with tetracycline
(Fig. 1C and D). In addition, most RNA foci were nuclear, but oc-
casional cytoplasmic (G4C2)n RNA foci were also detected (Fig.
1C). RNA foci were not detected in NSC34 sham cells (Fig. 1C). In
addition, RNAse A treatment ablated foci in the NSC34
(G4C2)102 cells (Fig. 1C).
The NSC34 (G4C2)102 cells were also examined for antisense
(C4G2)n RNA transcripts, using an antisense RNA FISH probe. As
expected, no antisense (C4G2)n RNA foci were detected in the
NSC34 (G4C2)102 cells (Fig. 2), because the (G4C2)n repeat is in-
dependent of the genomic C9ORF72 gene and any associated
promoter(s) that drive transcription in the antisense direction.
To demonstrate that we can detect antisense (C4G2)n RNA foci,
we transfected antisense (C4G2)102 constructs into HEK293
cells, as a positive control (Fig. 2).
In addition, immunoblotting was performed to detect trans-
lation products of the (G4C2)102 RNA. Translation of the
(G4C2)102 was predicted to change frame between DPR motifs
at each TCGAC interruption, and, therefore, translation prod-
ucts would contain a mixture of poly-GA, poly-GR, and poly-GP
stretches (Fig. 3A). NSC34 (G4C2)102 cells were immunoblotted
using anti-poly-GA, anti-poly-GR, anti-poly-GP, anti-poly-AP
and anti-poly-PR (Fig. 3B–F). HEK293 cells were transfected with
(GA)68, (GR)100, (AP)100 and (PR)100 constructs, and used as
positive controls for the respective antibodies (Fig. 3). There was
no available positive control for the anti-poly-GP antibody. The
anti-poly-GA, anti-poly-GR and anti-poly-GP antibodies all
detected proteins at 24 and 27 kDa in the NSC34 (G4C2)102 cells
treated with tetracycline (Fig. 3B–D), and these proteins were
more abundant in the tetracycline-treated NSC34 (G4C2)102
compared with untreated NSC34 (G4C2)102 cells (Fig. 3B–D). In
addition, these proteins were not detected in NSC34 sham, indi-
cating the (G4C2)102 RNA was translated to produce proteins
containing all three sense DPR motifs. Also, we concluded the
(G4C2)102 RNA was translated via RAN translation as there are
no ATG start sites preceding the (G4C2)102 construct in any
frame (Fig. 3A). Further, poly-AP and poly-PR are specifically
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Figure 1 NSC34 (G4C2)102 cells have tetracycline inducible (G4C2)102 RNA expression, which forms RNA foci. (A) Sequence of the (G4C2)102 construct. (B) Gel electro-
phoresis sizing the (G4C2)102 repeat constructs in the pcDNA5/FRT/TO-(G4C2)102 plasmids. (C) NSC34 sham and NSC34 (G4C2)102 cells were cultured for 3 days with
(or without) 0.5 mg/ml tetracycline. NSC34 (G4C2)102 cells were additionally treated with RNAse A as a control. Cells were stained with a locked nucleic acid (C4G2)3
sense probe (Red) and Dapi (Blue). Foci magnified 5 inset. Scale bar¼ 10 mm. (D) Average number of RNA foci per cell (***p<0.001; two-way ANOVA with Tukey’s mul-
tiple comparisons post hoc test; data shown are mean and SD; n¼3).
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Figure 2 NSC34 (G4C2)n cells do not transcribe (G4C2)n in the antisense direc-
tion. NSC34 sham and NSC34 (G4C2)102 cells were cultured for 3 days with
0.5 mg/ml tetracycline. Cells were stained with a locked nucleic acid (G4C2)3 anti-
sense probe (Red) and Dapi (Blue). HEK293 cells transfected with an antisense
(C4G2)102 plasmid contain (C4G2)102 foci and serve as a positive control. Scale
bar¼10 mm.
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translated from the antisense (C4G2)n RNA, and neither anti-
poly-AP nor anti-poly-PR detected any proteins specific to the
NSC34 (G4C2)102 cells compared with NSC34 sham cells (Fig. 3E
and F), supporting an absence of anti-sense (C4G2)n RNA tran-
scription and subsequent translation. Finally, translation prod-
ucts were also detected using the anti-poly-GA, anti-poly-GR
and anti-poly-GP antibodies in HEK293 cells containing the
same interrupted (G4C2)102 repeat construct (data not shown).
NSC34 (G4C2)102 cells recapitulate certain aspects of
ALS pathology
To validate the NSC34 (G4C2)102 cells as a model of C9ORF72-
ALS, they were assessed for biochemical changes that are
relevant to the pathophysiology of C9ORF72-ALS. First, we and
others have previously shown that several RNA binding pro-
teins (RBPs) such as Serine/Arginine-Rich Splicing Factor 1
(SRSF1), Serine/Arginine-Rich Splicing Factor 2 (SRSF2) and
Nucleolin (NCL) bind (G4C2)n RNA, and co-localise with (G4C2)n
RNA foci in C9ORF72-ALS cells (24,28). Tetracycline-induced
NSC34 (G4C2)102 cells were co-stained for sense (G4C2)n RNA
foci as well as either SRSF1, SRSF2 or NCL (Fig. 4A–C). We ana-
lysed 50 cells for each RBP co-stain. Of the (G4C2)n RNA foci
counted, 19.5% co-localised with SRSF1 puncta; 11.9% co-
localised with SRSF2 puncta; and 22.6% co-localized with nucle-
olar NCL (Fig. 4A–C). We have previously shown (G4C2)n RNA
foci co-localisation with SRSF2 in cerebellar granule cells and
motor neurons in C9ORF72-ALS patients (24). NCL was also
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Figure 3 The (G4C2)102 construct undergoes RAN translation in the NSC34 (G4C2)102 (G4C2)102 cells. (A) Schematic of translation products (including Stop codons)
from interrupted (G4C2)102 RNA construct in all three reading frames. GA, GP and GR repeats are highlighted in red, yellow and green, respectively. (B–F) NSC34 sham
and NSC34 (G4C2)102 cells were cultured for 7 days with (or without) 0.5 mg/ml tetracycline. HEK293 cells were transfected with (GA)68, (GR)100, (AP)100 and (PR)100
constructs to serve as a positive control for the respective DPR antibody. Cells were lysed and immunoblotted with anti-poly-GA (B), anti-poly-GR (C), anti-poly-GP (D),
anti-poly-AP (E) and anti-poly-PR (F). Arrows indicate the RAN translation products in the NSC34 (G4C2)102 cells. a-Tubulin was used as a loading control for blots.
Molecular weight markers are indicated (kDa).
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observed to co-localise with foci in cerebellar granule and
Purkinje neurons from C9ORF72-ALS patients (Fig. 4D).
Second, nucleolar stress is implicated in C9ORF72-ALS path-
ology (28). Here we detected a degree of disruption to the nucle-
olar morphology, in the NSC34 (G4C2)102 cells (Fig. 4E). The
nucleolar area as a percentage of the nucleus was increased by
38.669.8% (p< 0.01) in the NSC34 (G4C2)102þ tet vs. NSC34
sham cellsþ tet (Fig. 4E and F). There was no difference in the
overall nuclear area between the cell groups (data not shown).
This effect was much more apparent in motor neurons from the
ventral horn, but not glial cells, from C9ORF72-ALS patients
(Fig. 4G). To establish if the wider ALS pathological features of
TDP-43 mislocalisation or oxidative stress were also present in
this cellular model, immunofluorescence microscopy and
dichlorofluorescein (DCF) assays were performed on the NSC34
(G4C2)n cells. However, there was no TDP-43 mislocalisation or
aggregation (Supplementary Material, Fig. S1), or increase in oxi-
dative stress were observed in the NSC34 (G4C2)102 cells
(Supplementary Material, Fig. S2), compared with NSC34 sham
cells, at least under basal/unstressed cell culture conditions.
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Figure 4 NSC34 (G4C2)102 cells recapitulate pathological features of C9ORF72-ALS. (A–C, E) NSC34 (G4C2)102 cells were induced with 0.5 mg/ml tetracycline for 5 days.
Cells were then stained with a locked nucleic acid (C4G2)3 sense probe (Red), anit-SRSF1 (A), anti-SRSF2 (B) or anti-NCL (C) (all green), and Dapi (Blue). Scale bar¼10 mm.
(D) Cerebellar slices from C9ORF72-ALS cases were stained with a locked nucleic acid (C4G2)3 sense probe (Red), anti-NCL (green) and Dapi (Blue). Scale bar¼3 mm.
(E) NSC34 sham and NSC34 (G4C2)102 cells were stained for NCL (green) and DAPI (blue). Scale bar¼10 mm. (F) Quantification of NCL area as a percentage of nuclear
area in NSC34 sham and (G4C2)102 cells (*p<0.05; **p< 0.01; two-way ANOVA with Tukey’s multiple comparisons post hoc test; n¼3). (G) Ventral horn from C9ORF72-
ALS was stained for NCL and DAPI. Motor neurons (indicated with arrows and nuclei outlined) show disrupted NCL staining, while glial cells do not show disrupted
NCL staining. Scale bar¼3 mm.
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(G4C2)102 repeat induces cytotoxicity
Next, we assessed whether the (G4C2)102 repeat was toxic in
the motor neuronal NSC34 cells. The NSC34 cells were grown
for 7 days, and induced with tetracycline for increasing lengths
of time. The NSC34 (G4C2)102 showed reduced viability of
29.968.6% (p< 0.05) in an MTT assay after 7 days tetracycline
induction compared with NSC34 sham cells. In addition, tetra-
cycline exposure did not reduce viability in the NSC34 sham
cells (Fig. 5A). A growth curve was also performed on the NSC34
sham and NSC34 (G4C2)102 cells, with or without 0.5 mg/ml
tetracycline (Fig. 5B). Cells were cultured for 16 days in total, vi-
able cells were counted every 4 days and 1.5  106 cells were re-
seeded and cultured. There were significantly fewer viable
NSC34 (G4C2)102 cells when induced with tetracycline after 12
days compared with NSC34 sham cells6 tetracycline and NSC34
(G4C2)102 cells without tetracycline. Specifically, there were
only 66.8626.5% (p< 0.001) of NSC34 (G4C2)102þ tetracycline at
day 12 and 52.46 11.6% (p< 0.0001) at day 16 compared with
NSC34 shamþ tetracycline (Fig. 5B). In contrast, there were no
significant differences in the number of NSC34 sham with or
without tetracycline and NSC34 (G4C2)102 cells without
tetracycline.
(G4C2)n affects the PI3K/Akt signalling pathway at
transcriptomic level
We had previously undertaken transcriptome analysis on laser
captured microdissected (LCM) motor neurons from the spinal
cord of C9ORF72-ALS patients (30). Within this dataset, PTEN
(phosphatase and tensin homolog) had the highest fold change
of all differentially expressed genes (fold change¼þ 11.3,
p¼ 0.00001, Supplementary Material, Table 1). Additionally, pre-
vious transcriptome analysis on LCM motor neurons from spi-
nal cord motor neurons of SOD1-ALS patients showed that the
PI3K/Akt signalling pathway, negatively regulated by PTEN, was
increased in the surviving motor neurons, and may provide a
therapeutic target (54). Therefore, we investigated the PI3K/Akt
signalling pathway in the Kyoto Encyclopaedia of Genes and
Genomes (KEGG), in both the human C9ORF72-ALS LCM motor
neurons and the murine NSC34 (G4C2)n cells. Careful statistical
analysis revealed that this pathway was significantly dysregu-
lated in LCM motor neurons carrying the (G4C2)n C9ORF72 re-
peat expansion (rank-product, p¼ 0.01), and the NSC34 cells
expressing the (G4C2)102 repeat (rank-product, p< 0.00001).
Transcripts in the PI3K/Akt signalling pathway (KEGG) are listed
in Supplementary Tables 1 and 2 for human motor neurons and
murine NSC34 cells, respectively.
PTEN single nucleotide polymorphism (SNP) associated
with protection against ALS
We also examined a large genome wide association study
(GWAS) using the NeuroX chip (55) to genotype 4890 ALS cases
and 5649 normal controls; the NeuroX chip includes genotyping
of standard Illumina exome content of approximately 240 000
variants, and additionally, more than 24 000 custom content
variants to improve coverage in genes associated with neuro-
logical diseases. A list of SNPs found in PTEN was identified
using BioMart (56). The threshold for significant association
with the ALS phenotype was set as a Benjamini–Hochberg-cor-
rected false discovery rate (FDR)< 0.05, which is appropriate for
a hypothesis-based rather than a screening-based approach. A
single SNP in PTEN was associated with risk of ALS (FDR¼ 0.005).
The minor (A) allele of rs202004587 was five times more com-
mon in controls than in ALS patients. The minor allele is a mis-
sense change which has been associated with hereditary
neoplasms by clinical testing (http://www.ncbi.nlm.nih.gov/clin
var/RCV000129085/) and is, therefore, thought to be associated
with loss of PTEN function (57). Based on our data, the minor al-
lele should, therefore, be protective against ALS. This further
validates the transcriptomic findings from our cell model, and
C9ORF72-ALS LCM motor neurons, and suggests that PTEN
function could be an important therapeutic target for all ALS. It
is possible that the SNP we have identified is in linkage disequi-
librium with another more functionally significant variant in
the PTEN gene; however, since we are relying on a GWAS data-
set with incomplete coverage of the PTEN gene, it is not possible
to explore this further with the current data-set.
Partial Pten knockdown rescues (G4C2)102-induced
toxicity
Up-regulation of Pten is consistent with inhibition of the PI3K/
Akt signalling pathway. This led us to hypothesise that reducing
the expression of Pten in the C9ORF72 in vitro model system
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might rescue the observed (G4C2)n-induced toxicity. NSC34
sham and NSC34 (G4C2)102 were both stably transduced with a
lentivirus (LV) expressing either Pten shRNA, or GFP (as a con-
trol). Pten was knocked down by 566 7.6% (p< 0.05) in the
NSC34 sham cells stably transduced with Pten shRNA LV com-
pared with the NSC34 sham cells stably transduced with control
GFP LV, and 62.5622.7% (p< 0.01) in the NSC34 (G4C2)102 cells
stably transduced with Pten shRNA LV compared with the
NSC34 (G4C2)102 cells stably transduced with control GFP LV
(Fig. 6A). Additionally, Pten knockdown does not significantly
affect the number of RNA foci in the transduced NSC34
(G4C2)102 cells (Supplementary Material, Fig. S4), suggesting
that this manipulation does not affect the (G4C2)102 RNA level.
The LV transduced NSC34 cells were then grown for 7 days,
with or without tetracycline, and viability was assessed. As ex-
pected, we detected a significant reduction (21.16 9.1%; p< 0.01)
in the NSC34 (G4C2)102 GFP LV cell viability when induced with
tetracycline (Fig. 6B). However, there was no significant reduc-
tion in the NSC34 (G4C2)102 Pten shRNA LV cell viability when
induced with tetracycline (Fig. 6B). Therefore, the partial Pten
knockdown rescues the NSC34 cells from (G4C2)n-induced tox-
icity. These results were also replicated using NSC34 sham and
(G4C2)102 cells that were transduced with LV expressing
scrambled shRNA where the expected cytotoxicity was
observed (data not shown). Modulation of PTEN may, therefore,
provide a potential therapeutic approach to ameliorate the toxic
effects of (G4C2)n-induced toxicity in C9ORF72-ALS.
Discussion
Recently, various studies have attempted to elucidate the toxic
function associated with the (G4C2)n repeat expansion in
C9ORF72, which is the most common genetic cause of ALS and
FTD (1,2). The repeat expansion is thought to either cause neur-
onal injury through loss of C9ORF72 function (haploinsuffi-
ciency), and/or a gain-of-toxic function from the RNA or DPR
proteins. Although there is still much to learn, emerging evi-
dence strongly supports a gain-of-toxic function. First, multiple
studies show that the (G4C2)n RNA and/or DPR proteins cause
toxicity and/or neurodegeneration in various model systems.
Second, while studies interrogating C9ORF72 loss-of-function
have reported microglial pathology, they have not reported
motor neuron degeneration or TDP-43 pathology associated
with C9ORF72 knock down in mice (13,16–21). Third, the tar-
geted knockdown of C9ORF72 transcripts using ASOs rescues
toxicity, and associated transcriptomic changes in cellular mod-
els from C9ORF72-ALS/FTD patients (9,20,27).
To investigate the early biochemical changes caused by
(G4C2)n repeat expression, we generated stable, isogenic motor
neuron-like cell lines with inducible expression of interrupted
(G4C2)n repeat constructs. The interrupted (G4C2)102 repeat
constructs produced (G4C2)n RNA foci, and underwent RAN
translation in the NSC34 (G4C2)n cells, recapitulating key patho-
logical features of C9ORF72-ALS/FTD patient cells. Not surpris-
ingly, there were no antisense-derived RNA foci or RAN
translation products in the NSC34 (G4C2)n cells, making this
model a sense-only (G4C2)n gain-of-function model. We believe
that the new in vitro model we have generated will prove useful
for screening compounds that modulate the number of RNA
foci, the burden of RAN translation products, or the cytotoxicity
relating to the presence of the C9ORF72 G4C2 expansion.
However, while the NSC34 (G4C2)102 cells did recapitulate
both the RNA foci and RAN translation of the (G4C2)102 repeat,
we did not detect TDP-43 proteinopathy or oxidative stress (two
pathological hallmarks of ALS) under basal culture conditions.
We did detect colocalisation of the SRSF1, SRSF2 and NCL with
the (G4C2)n RNA foci, which is consistent with both C9ORF72-
ALS/FTD CNS tissue, and other cellular models expressing the
(G4C2)n repeat expansion. Therefore, we reasoned that any bio-
chemical and transcriptomic effects we detected in this cellular
model system will represent early changes in response to the
presence of the (G4C2)102 repeat. Further, and in agreement
with previous studies, the (G4C2)102 repeat reduced NSC34 cell
viability and growth rate. However, this could have been caused
by either the (G4C2)n RNA foci or the RNA translation proteins
produced by the (G4C2)102 transcripts. This is consistent with
the literature, showing a gain-of-toxic function associated with
the (G4C2)n repeat expansion either through direct RNA toxicity
or associated RAN translation protein toxicity (9,20,27,41).
Interestingly, however, the proteins generated in this model are
hybrids of all sense DPR proteins. There are three possible ex-
planations for the motor neuronal toxicity observed in our
model system: (1) the toxicity could be due to the (G4C2)102
RNA alone; (2) the sense DPR motifs may be toxic even when co-
occurring in the same polypeptide; (3) the RAN proteins confer
toxicity through the poly-GR stretches.
Once we could detect toxicity in the model, the main aim
was to use the model for identifying potential therapeutic tar-
gets for C9ORF72-ALS/FTD. As a first step towards this goal, we
performed transcriptomic analysis on the NSC34 (G4C2)102 cell
model. Importantly, using our inducible model system, any
A
B C
Figure 6 Pten knockdown rescues NSC34 cells from (G4C2)102-induced toxicity.
(A) Cells were lysed and immunoblotted with anti-Pten. b-Actin was used as a
loading control for blots. Molecular weight markers are indicated (kDa). (B)
Quantification of Pten normalised to b-actin (*p<0.05; **p<0.01; one-way
ANOVA with Tukey’s multiple comparisons post hoc test; data shown are mean
and SD; n¼3). (C) NSC34 sham GFP, NSC34 (G4C2)102 GFP, NSC34 sham Pten
shRNA and NSC34 (G4C2)102 Pten shRNA cells were cultured for 7 days, with (or
without) 0.5 mg/ml tetracycline. Cell viability was measured using an MTT assay,
and the viability of the tetracycline induced cells was normalised to the non-
induced control for each individual cell line (**p< 0.01; two-way ANOVA with
Sidak’s multiple comparisons post hoc test; data shown are mean and SD; n¼3).
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changes detected are likely to be the early transcriptomic
changes associated with any gain-of-toxic function from the
(G4C2)102 repeat. We identified the novel finding that the
(G4C2)n repeat dysregulates the PI3K/Akt signalling pathway in
a motor neuronal model of C9ORF72-ALS. Further, we validated
this finding using transcriptomic analysis of LCM motor neu-
rons from C9ORF72-ALS cases. This is also consistent with pre-
vious transcriptome analysis on LCM motor neurons from
spinal cord of SOD1-ALS patients (54), implicating the pathway
in a broader ALS context. Within the C9ORF72-ALS dataset,
PTEN had the highest fold change of all DE genes, and previous
work has shown PTEN knockdown via siRNA promotes motor
neuron survival in ALS and SMA models (54,58,59). Therefore,
we partially knocked down Pten in the NSC34 (G4C2)102 cells,
which rescued the cells from the (G4C2)102 repeat induced tox-
icity. Finally, we present evidence from a GWAS study that loss
of PTEN function may be protective against ALS more broadly.
Taken together, the data we present suggest that PTEN may rep-
resent a potential therapeutic target in C9ORF72-ALS, but may
also be relevant in other subtypes of ALS.
Materials and Methods
Generation of interrupted (G4C2)n repeat constructs
The interrupted (G4C2)102 repeat construct was generated by
restriction digest and ligation. Synthesised TCGAC(G4C2)10
sense and ACGT(G2C4)10 antisense ssDNA oligonucleotides
(Sigma-Aldrich) were designed so that the dsDNA produced by
annealing the oligonucleotides is flanked 50 by SalI and 30 by
XhoI restriction sites. The ssDNA oligos were denatured at 99C
for 30 min and then annealed by reducing the temperature by
0.5 C/min. These (G4C2)10 were ligated into SalI and XhoI cut
pcDNA6.2-GW/EmGFP-miR (Invitrogen), to generate pcDNA6.2-
GW/EmGFP-(G4C2)10. Subsequent ligations involved XhoI
cutting pcDNA6.2-GW/EmGFP-(G4C2)n vectors and inserting
further (G4C2)10 repeats. The 50 SalI site of the inserted (G4C2)n
was destroyed whilst the 30 XhoI site was retained – if the inser-
tion orientation was correct. pCMV-EmGFP-(G4C2)102 vectors
containing 102 repeats were generated via this method. The
exact sequence of the (G4C2)102 construct is described in
Figure 1A. EmGFP was subsequently removed from these vec-
tors by DraI digestion and religation.
The (G4C2)102 construct was subcloned into pcDNA5/FRT/
TO HIS (Addgene) using DraI and XhoI restriction sites. The
FRT/TO/(G4C2)n plasmids were then HindIII and BamHI cut,
Klenow treated and subsequently PNK treated and religated.
Transformations of plasmids containing the (G4C2)n repeat
constructs were performed using recombination-deficient b-10
Escherichia coli (NEB) to minimise (G4C2)n repeat shrinkage. All
constructs were checked by sequencing at regular intervals.
Plasmids were extracted using a NucleoSpin Plasmid kit
(Macherey-Nagel), according to the instructions of the
manufacturer.
Generation of NSC34 (G4C2)102 cell models
Flp-InTM T-RExTM murine motor neuron-like NSC34 cells were
generated in house using the Flp-InTM T-RExTM Core Kit
(Invitrogen) according to the instructions of the manufacturer.
Briefly, an FRT site and tetracycline repressor element were in-
serted independently into the NSC34 cell genome, and the best
clone was selected. Then, pcDNA5/FRT/TOVC and pcDNA5/FRT/
TO-(G4C2)102 plasmids were stably integrated into the Flp-InTM
T-RExTM NSC34 host cell line generating isogenic NSC34 sham
and NSC34 (G4C2)102 cell lines, respectively. NSC34 (G4C2)102
cells had tetracycline inducible expression of the inserted
(G4C2)102 construct.
Cell culture, cell line maintenance, plasmid transfection
and lentiviral transduction
To maintain the cell lines, the NSC34 sham and NSC34
(G4C2)102 cells were cultured in supplemented DMEM (10% FBS,
tetracycline-free (Biosera), 50 U/ml penicillin/streptomycin
(Lonza Group Ltd), 100 lg/ml Hygromycin B (Invitrogen), 5 lg/ml
Blasticidin (Invitrogen) in a 37C/5% CO2 incubator. Media was
replaced every 2–3 days. NSC34 sham and (G4C2)102 cells that
were stably transduced with the lentiviral vectors additionally
had 1 mg/ml puromycin selection in the supplemented DMEM.
HEK293 cells were cultured in supplemented DMEM (10% FBS
(Sigma-Aldrich), 50 U/ml penicillin/streptomycin) in a 37C/5%
CO2 incubator. NSC34 and HEK293 cells were seeded at an ap-
propriate density, such that the cells were 70-80% confluent at
the experimental end point.
For imaging, NSC34 cells were seeded onto gelatin coated
coverslips. For each ml of media on the HEK293, 1.4 lg plasmid
DNA and 5 lg PEI were diluted in 100 lL OptiMEM (Life
Technologies), and added dropwise to the media on cells. Cells
were incubated for 24 h.
For the lentiviral transduction, NSC34 sham and NSC34
(G4C2)102 cells were transduced with PTEN shRNA (mouse) len-
tiviral particles (Santa Cruz; sc-36326-V), cop GFP Control lenti-
viral particles (Santa Cruz; sc-108084), or Control shRNA
lentiviral particles (Santa Cruz; sc-108080). Stable transformants
were selected for using 1 mg/ml puromycin.
NSC34 (G4C2)n cell line tetracycline induction
About 0.5 mg/ml tetracycline (Invitrogen) was added to NSC34
(G4C2)n cell media, to induce (G4C2)n RNA expression.
Tetracycline was added every 3 days (if applicable) to maintain
concentration in the media.
Immunoblotting
NSC34 and HEK293 cells were grown on 6-well plates until 80%
confluent. Cells were lysed in lysis buffer (150 mM NaCl,
Protease Inhibitor Cocktail EDTA–free (Roche; used to according
to the instructions of the manufacturer)) on ice for 20 min.
Lysates were centrifuged at 17 000  g at 4 C for 5 min to clarify.
Supernatant was incubated with Laemmli buffer at 95C for
5 min. 25 lg protein from NSC34 lysate and 25 lg protein from
HEK293 lysates were separated on 12% or 15% Tris-glycine SDS-
polyacrylamide gels and transferred to AmershamTM ProtranTM
Premium 0.2 nitrocellulose membrane (GE Healthcare).
Membranes were blocked in 5% milk (Marvel) in TBS-T at RT for
1 h. Membranes were then probed with mouse anti-GA (1 in 200;
kindly provided by Prof Dieter Edbauer), rabbit anti-GP, rabbit
anti-GR, rabbit anti-PR, rabbit anti-PA (all 1 in 2000; kindly pro-
vided by Prof Stuart Pickering-Brown), rabbit monoclonal anti-
PTEN (1 in 1000, Cell Signalling Technology, #9188), mouse
monoclonal anti-b actin (1 in 10 000, Abcam, AC-15), or mouse
monoclonal anti-a tubulin (1 in 10 000; Sigma-Aldrich; clone
DM1A), in 5% Milk/TBS-T at RT for 1 h. Membranes were
washed three times in TBS-T, then probed with goat polyclonal
anti-rabbit-IgG HRP (1 in 5000; DAKO) or goat polyclonal
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anti-mouse-IgG HRP (1 in 5000; DAKO) in 5% Milk/TBT at RT for
1 h. Membranes were washed three times in TBS-T. Bands were
visualised with EZ ECL chemiluminescence detection kit for
HRP (Geneflow Ltd) according to the instructions of the manu-
facturer and imaged using a G-BOX (Syngene).
RNA fish
A 5’ TYE-563-labelled LNA (16-mer fluorescent)-incorporated
DNA probe was used against the sense and antisense RNA hex-
anucleotide repeat (Exiqon Inc., batch numbers 607323 and
515905, respectively). Slides with tissue were fixed in 4% paraf-
ormaldehyde for 10 min. Before use, formalin fixed paraffin-
embedded tissue sections were deparaffinized. Slides with
NSC34 and HEK293 cells were fixed and permeabilised in 4%
PFA/0.2% Triton X-100 for 20 min. For the RNAse-treated control,
slides were incubated with 10 lg/ml RNAse A at 37C for 30 min.
Slides were blocked with hybridization solution [50% forma-
mide, 2  saline sodium citrate (SSC), 100 mg/ml dextran sul-
phate, 50 mM sodium phosphate pH 7.0] at 66C for 1 h and then
incubated with 400 ng/ml of denatured probe in hybridization
solution at 66 C overnight. After hybridization, slides were
washed once in 2  SSC/0.1% Tween-20 at RT for 5 min and
three times in 0.1  SSC at 65C for 10 min. NSC34 cells that
were subsequently dual stained by immunocytochemistry (ICC)
were first irradiated on ice with 0.3 J/cm2 UV, washed three
times with PBS, and then ICC staining was performed. Slides
were mounted with mounting medium containing DAPI (Vector
Labs Inc.). All solutions were made with DEPC-treated water.
Immunocytochemistry and immunohistochemistry
Slides with NSC34 cells were fixed and permeabilised in 4% PFA/
0.2% Triton X-100 at RT for 20 min. Slides were incubated with
rabbit polyclonal anti-TDP-43 (1 in 200, Proteintech, 10782-2-
AP), rabbit polyclonal anti-SRSF1 (1 in 200, Abcam ab38017),
mouse monoclonal anti-SRSF2 (1 in 200, Abcam ab11826), or
rabbit polyclonal anti-NCL (1:200; Proteintech; 10556-1-AP) in 2%
BSA in PBS at RT for 1 h. Slides were washed three times in PBS,
then incubated with goat anti-rabbit IgG H&L (1 in 1000; Alexa
FluorVR 488; Abcam) or goat anti-mouse IgG H&L (1 in 1000; Alexa
FluorVR 488; Abcam) in 2% BSA in PBS at RT for 1 h. Formalin fixed
paraffin-embedded tissue sections were deparaffinized and
mouse anti-NCL (1 in 150 in 5% BSA; Abcam; ab136649) stained
slides were first antigen retrieved by heat in trisodium citrate
pH 6.5 for 20 min, then completed as for ICC. Slides of NSC34
and tissue sections were mounted with mounting medium con-
taining DAPI (Vector Labs Inc.).
Microscopy imaging
RNA foci and RBP: RNA foci were visualised using a Leica SP5 con-
focal microscope system with a X63/1.4 oil immersion objective
lens. The presence of foci was assessed within a high-resolution
(1433 mm2 per image, 511  511 pixels) z-stack made up of
images at 0.13 mm intervals through the entire nuclear volume
of the cell under consideration. RNA foci were quantified manu-
ally. The same imaging was used for RNA foci and RBP (SRSF1,
SRSF2 and NCL) co-staining, and for each RBP foci co-stain 50
NSC34 (G4C2)102 cells were analysed for co-localisation.
NCL: NCL staining in the NSC34 cells and tissue was visual-
ised using a Leica SP5 confocal microscope system with an X63/
1.4 oil immersion objective lens. (3775 mm2 per image, 511  511
pixels) z-stack made up of images at 0.5-mm intervals through
the entire nuclear volume of the cell under consideration. To
quantify the NCL area relative to the nuclear area, we used the
analysis previously described by Haeusler et al. 2014 (28). Briefly,
a threshold of 50–100 was set in FIJI to measure the nucleolar
NCL area, relative to the nuclear area (defined by DAPI staining).
Data are means6SD n¼ 3 for NSC34 cells.
TDP-43: TDP-43 staining in NSC34 cells were visualised using
a Nikon DS Ri1 Eclipse.
MTT assay
NSC34 cells were grown for 7 days on a 96-well plate. 0.5 mg/ml
tetracycline was added to media, and re-added every 3 days.
After 7 days incubation, 0.5 mg/ml MTT reagent (Sigma-Aldrich)
was added to media. Plates were incubated in a 37C/5% CO2 in-
cubator for 90 min. One volume SDS/DMF (20% sodium dodecyl
sulphate in 50% dimethyl formamide, pH 4.7) was added to lyse
cells. An absorbance of 595 nm of wells was assessed using a
PHERAstar FS plate reader (BMG Labtech Ltd).
DCF assay
NSC34 cells were grown on 96-well plates for 5 days. 0.5 mg/ml
tetracycline was added to media and re-added every 3 days.
After 5 days incubation, media was replaced with supplemented
phenol-red free DMEM (Lonza)þ 10% FBS, tetracycline free
(Biosera). Cytosolic reactive oxygen species levels were meas-
ured using 6-carboxy-20,70-dichlorodihydrofluorescein diacetate,
di(acetoxymethyl ester) (DCF; Molecular ProbesTM, Life
Technologies, C-2938) fluorescence. DCF was added to NSC34
cells at 10 mM, and cells were incubated at 37 C for 90 min. The
fluorescence of oxidised DCF was read at Ex485 nm/Em520 nm
using a PHERAstar FS plate reader (BMG labtech Ltd). Cells were
then freeze-thawed, and cell number was measured by adding
1.5 mM Ethidium homodimer-1 (EthD1, Molecular ProbesTM, Life
Technologies) to the medium. Fluorescence was measured at
Ex570 nm/Em610 nm. Raw DCF data were then normalised to
EthD1 reading of cell number.
RNA preparation for microarray
NSC34: Three replicate sets of NSC34 cells were cultured for 5
days with or without tetracycline. Media and tetracycline
(where necessary) were replenished every 3 days. RNA was ex-
tracted using TRI-ReagentVR (Zymo Research) and a Direct-zolTM
RNA MiniPrep kit (Zymo Research) according to the instructions
of the manufacturer. RNA quantity and quality was assessed
on the Nanodrop spectrophotometer (Thermofisher) and a
Bioanalyser (Agilent), respectively, to ensure all samples were of
comparable and sufficient quality to proceed.
Laser capture microdissected (LCM) Motor Neuron Microarray:
Refer to Cooper-Knock et al. 2015 (30).
Microarray hybridisation
NSC34: Total RNA (500 ng) was linearly amplified using the
GeneChipVR WT PLUS Reagent kit (Affymetrix) according to the
instructions of the manufacturer, to produce ss-cDNA. ss-cDNA
(5.5 mg) was fragmented and labelled with biotin, then applied
to the GeneChipVR Mouse Whole Transcript 1.0 ST Array
(Affymetrix), according to the instructions of the manufacturer.
Three chips were used for each NSC34 cell line and tetracycline
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induction condition. Array washing and staining was performed
in the Fluidics Station 400 according to the Affymetrix protocol.
Arrays were scanned using the Affymetrix GeneChipVR 3000 7G
scanner. The Affymetrix Gene Chip Command Console
(Affymetrix) was used to monitor scanning and to convert the
raw image file into a cell intensity file (‘.CEL’).
LCM Motor Neurons: Refer to Cooper-Knock et al. 2015 (30).
RNA (20–25 ng) was linearly amplified using the Affymetrix Two
Cycle cDNA synthesis protocol to produce biotin-labelled copy
RNA. Copy RNA (15lg) was fragmented for 15 min and hybri-
dized to the Human Genome U133 Plus 2.0 GeneChips, accord-
ing to Affymetrix protocols. Array washing and staining was
performed as above.
Gene expression data analysis
NSC34 :For the mouse microarrays, RMA normalisation was per-
formed. 61 transcripts within the murine PI3K/Akt signalling
pathway (KEGG) were measured on the Mouse Whole
Transcript microarray platform in the NSC34 cells
(Supplementary Material, Table S2). PCA analysis without statis-
tical manipulation revealed a distinct separation between
NSC34 (G4C2)102 and NSC34 sham cells (Supplementary
Material, Fig. S3). In order to interrogate this signal further, ex-
pression of all transcripts was ranked according to t-statistic in
a comparison between NSC34 (G4C2)102 and NSC34 sham cell
lines. The combined rank-product (60) of transcripts from the
PI3K/Akt signalling pathway was compared to 100 000 random
permutations of the same number of transcripts. In short, the
product of (rank transcript X/total number of transcripts) was cal-
culated where transcript X was each member of the PI3K/Akt
pathway in turn; then the probability that this rank-product
occurred by ‘chance’ was determined by comparison with ran-
dom selections of the same number of transcripts where each
rank is equally probable. Differential expression of individual
transcripts (Supplementary Material, Table S2) was examined
by t-test and fold change.
LCM Motor Neurons: Data from the laser captured microdis-
section motor neurons were normalised using the PUMA pack-
age (61,62). Around 283 transcripts within the human PI3K/Akt
signalling pathway (KEGG) were measured on the Human U133-
Plus 2.0 microarray platform in the laser-captured motor
neurons (Supplementary Material, Table S1). Expression of all
transcripts was ranked according to t-statistic in a comparison
between motor neurons with and without expansion of
C9ORF72. The combined rank-product (60) of transcripts from
the PI3K/Akt signalling pathway was compared with 100 000
random permutations of the same number of transcripts.
Differential expression of individual transcripts (Supplementary
Material, Table S1) was examined by t-test and fold change.
GWAS analysis
GWAS data were examined using PLINK (http://pngu.mgh.har
vard.edu/purcell/plink/ (63)). Genomes were screened from 4890
ALS patients and 5191 controls including 5649 males and 4432
females. All genomes were founders i.e. no two individuals
were related to each other. Association analysis was performed
and adjusted for multiple testing using the Benjamini and
Benjamini & Hochberg (1995) step-up false discovery rate (FDR)
control (64). At a significance level of FDR< 0.05, rs202004587
was significantly associated with risk of ALS. Repeating this
analysis for a random selection of 500 genes, with
approximately the same number of SNPs as PTEN, further sug-
gested that this finding was significant (p< 0.05).
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We are grateful to Prof. Dieter Edbauer and Prof. Stuart Pickering
Brown for kindly supplying antibodies to the dipeptide repeat
proteins.
Conflict of Interest statement. None declared.
Funding
This work was supported in part by the European Community’s
Seventh Framework Programme [FP7/2007-2013] under the
EuroMOTOR project [Grant agreement no. 259867 to J.K., P.J.S.
and A.C.]; P.J.S. is also supported as a National Institute for
Health Research Senior Investigator and by the Medical
Research Council; a Motor Neuron Disease Association/Medical
Research Council Lady Edith Wolfson Fellowship award [MR/
K003771/1 to J.C.K.]; and the Sheffield Hospitals Charitable Trust
(Grant no. 131425 to J.K. and M.S.). The Italian Ministry of Health
(Ricerca Sanitaria Finalizzata 2010, Grant RF-2010-2309849), the
Agenzia Italiana per la Ricerca sulla SLA (ARISLA) (Sardinials
project) (to A.C.). This work was supported in part by the
Intramural Research Programs of the NIH, National Institute on
Aging (Z01-AG000949-02 to B.J.T.). The work was also supported
by the Agency of Toxic Substances and Disease Registry, Center
for Disease Control (to B.J.T.). Funding for Open Access was pro-
vided by the University of Sheffield.
References
1. DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer,
A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A.,
Flynn, H., Adamson, J., et al. (2011) Expanded GGGGCC hexa-
nucleotide repeat in noncoding region of C9ORF72 causes
chromosome 9p-linked FTD and ALS. Neuron, 72, 245–256.
2. Renton, A.E., Majounie, E., Waite, A., Simon-Sanchez, J.,
Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van
Swieten, J.C., Myllykangas, L., et al. (2011) A hexanucleotide
repeat expansion in C9ORF72 is the cause of chromosome
9p21-linked ALS-FTD. Neuron, 72, 257–268.
3. Beer, A.M., Cooper-Knock, J., Higginbottom, A., Highley, J.R.,
Wharton, S.B., Ince, P.G., Milano, A., Jones, A.A., Al-Chalabi,
A., Kirby, J., et al. (2015) Intermediate length C9orf72 expan-
sion in an ALS patient without classical C9orf72 neuropath-
ology. Amyotroph. Lateral Scler. Frontotemporal Degener, 16,
249–251.
4. Byrne, S., Heverin, M., Elamin, M., Walsh, C. and Hardiman,
O. (2014) Intermediate repeat expansion length in C9orf72
may be pathological in amyotrophic lateral sclerosis.
Amyotroph. Lateral Scler. Frontotemporal Degener, 15, 148–150.
5. Cooper-Knock, J., Shaw, P.J. and Kirby, J. (2014) The widening
spectrum of C9ORF72-related disease; genotype/phenotype
correlations and potential modifiers of clinical phenotype.
Acta Neuropathol., 127, 333–345.
6. Almeida, S., Gascon, E., Tran, H., Chou, H.J., Gendron, T.F.,
Degroot, S., Tapper, A.R., Sellier, C., Charlet-Berguerand, N.,
Karydas, A., et al. (2013) Modeling key pathological features
1142 | Human Molecular Genetics, 2017, Vol. 26, No. 6
of frontotemporal dementia with C9ORF72 repeat expansion
in iPSC-derived human neurons. Acta Neuropathol., 126,
385–399.
7. Ciura, S., Lattante, S., Le Ber, I., Latouche, M., Tostivint, H.,
Brice, A. and Kabashi, E. (2013) Loss of function of C9orf72
causes motor deficits in a zebrafish model of Amyotrophic
Lateral Sclerosis. Ann. Neurol., 74, 180–187.
8. Belzil, V.V., Bauer, P.O., Prudencio, M., Gendron, T.F., Stetler,
C.T., Yan, I.K., Pregent, L., Daughrity, L., Baker, M.C.,
Rademakers, R., et al. (2013) Reduced C9orf72 gene expres-
sion in c9FTD/ALS is caused by histone trimethylation, an
epigenetic event detectable in blood. Acta Neuropathol., 126,
895–905.
9. Donnelly, C.J., Zhang, P.W., Pham, J.T., Haeusler, A.R.,
Heusler, A.R., Mistry, N.A., Vidensky, S., Daley, E.L., Poth,
E.M., Hoover, B., et al. (2013) RNA toxicity from the ALS/FTD
C9ORF72 expansion is mitigated by antisense intervention.
Neuron, 80, 415–428.
10. Waite, A.J., B€aumer, D., East, S., Neal, J., Morris, H.R.,
Ansorge, O. and Blake, D.J. (2014) Reduced C9orf72 protein
levels in frontal cortex of amyotrophic lateral sclerosis and
frontotemporal degeneration brain with the C9ORF72 hexa-
nucleotide repeat expansion. Neurobiol. Aging, 35,
1779.e1775-1779. e1713.
11. Xiao, S., MacNair, L., McGoldrick, P., McKeever, P.M., McLean,
J.R., Zhang, M., Keith, J., Zinman, L., Rogaeva, E. and
Robertson, J. (2015) Isoform-specific antibodies reveal dis-
tinct subcellular localizations of C9orf72 in amyotrophic lat-
eral sclerosis. Ann. Neurol., 78, 568–583.
12. Therrien, M., Rouleau, G.A., Dion, P.A. and Parker, J.A. (2013)
Deletion of C9ORF72 results in motor neuron degeneration
and stress sensitivity in C. elegans. PLoS One, 8, e83450.
13. Sullivan, P.M., Zhou, X., Robins, A.M., Paushter, D.H., Kim, D.,
Smolka, M.B. and Hu, F. (2016) The ALS/FTLD associated pro-
tein C9orf72 associates with SMCR8 and WDR41 to regulate
the autophagy-lysosome pathway. Acta Neuropathol.
Commun., 4, 51.
14. Yang, M., Liang, C., Swaminathan, K., Herrlinger, S., Lai, F.,
Shiekhattar, R. and Chen, J.F. (2016) A C9ORF72/SMCR8-
containing complex regulates ULK1 and plays a dual role in
autophagy. Sci. Adv., 2, e1601167.
15. Webster, C.P., Smith, E.F., Bauer, C.S., Moller, A., Hautbergue,
G.M., Ferraiuolo, L., Myszczynska, M.A., Higginbottom, A.,
Walsh, M.J., Whitworth, A.J., et al. (2016) The C9orf72 protein
interacts with Rab1a and the ULK1 complex to regulate initi-
ation of autophagy. EMBO J., 35, 1656–1676.
16. Burberry, A., Suzuki, N., Wang, J.Y., Moccia, R., Mordes, D.A.,
Stewart, M.H., Suzuki-Uematsu, S., Ghosh, S., Singh, A.,
Merkle, F.T., et al. (2016) Loss-of-function mutations in the
C9ORF72 mouse ortholog cause fatal autoimmune disease.
Sci. Transl. Med., 8, 347ra393.
17. Atanasio, A., Decman, V., White, D., Ramos, M., Ikiz, B., Lee,
H.C., Siao, C.J., Brydges, S., LaRosa, E., Bai, Y., et al. (2016)
C9orf72 ablation causes immune dysregulation character-
ized by leukocyte expansion, autoantibody production, and
glomerulonephropathy in mice. Sci. Rep., 6, 23204.
18. O’Rourke, J.G., Bogdanik, L., Ya~nez, A., Lall, D., Wolf, A.J.,
Muhammad, A.K., Ho, R., Carmona, S., Vit, J.P., Zarrow, J.,
et al. (2016) C9orf72 is required for proper macrophage and
microglial function in mice. Science, 351, 1324–1329.
19. Sudria-Lopez, E., Koppers, M., de Wit, M., van der Meer, C.,
Westeneng, H.J., Zundel, C.A., Youssef, S.A., Harkema, L., de
Bruin, A., Veldink, J.H., et al. (2016) Full ablation of C9orf72 in
mice causes immune system-related pathology and
neoplastic events but no motor neuron defects. Acta
Neuropathol., 132, 145–147.
20. Lagier-Tourenne, C., Baughn, M., Rigo, F., Sun, S., Liu, P., Li,
H.R., Jiang, J., Watt, A.T., Chun, S., Katz, M., et al. (2013)
Targeted degradation of sense and antisense C9orf72 RNA
foci as therapy for ALS and frontotemporal degeneration.
Proc. Natl. Acad. Sci. USA, 110, E4530–E4539.
21. Koppers, M., Blokhuis, A.M., Westeneng, H.J., Terpstra, M.L.,
Zundel, C.A., Vieira de Sa, R., Schellevis, R.D., Waite, A.J.,
Blake, D.J., Veldink, J.H., et al. (2015) C9orf72 ablation in mice
does not cause motor neuron degeneration or motor deficits.
Ann. Neurol., 78, 426–438.
22. Gendron, T.F., Bieniek, K.F., Zhang, Y.J., Jansen-West, K.,
Ash, P.E., Caulfield, T., Daughrity, L., Dunmore, J.H.,
Castanedes-Casey, M., Chew, J., et al. (2013) Antisense tran-
scripts of the expanded C9ORF72 hexanucleotide repeat
form nuclear RNA foci and undergo repeat-associated non-
ATG translation in c9FTD/ALS. Acta Neuropathol., 126,
829–844.
23. Renoux, A.J. and Todd, P.K. (2012) Neurodegeneration the
RNA way. Prog. Neurobiol., 97, 173–189.
24. Cooper-Knock, J., Walsh, M.J., Higginbottom, A., Robin
Highley, J., Dickman, M.J., Edbauer, D., Ince, P.G., Wharton,
S.B., Wilson, S.A., Kirby, J., et al. (2014) Sequestration of mul-
tiple RNA recognition motif-containing proteins by C9orf72
repeat expansions. Brain, 137, 2040–2051.
25. Lee, Y.B., Chen, H.J., Peres, J.N., Gomez-Deza, J., Attig, J.,
Stalekar, M., Troakes, C., Nishimura, A.L., Scotter, E.L.,
Vance, C., et al. (2013) Hexanucleotide repeats in ALS/FTD
form length-dependent RNA foci, sequester RNA binding
proteins, and are neurotoxic. Cell Rep., 5, 1178–1186.
26. Mori, K., Lammich, S., Mackenzie, I.R.A., Forne, I., Zilow, S.,
Kretzschmar, H., Edbauer, D., Janssens, J., Kleinberger, G.,
Cruts, M., et al. (2013) hnRNP A3 binds to GGGGCC repeats
and is a constituent of p62-positive/TDP43-negative inclu-
sions in the hippocampus of patients with C9orf72 muta-
tions. Acta Neuropathol., 125, 413–423.
27. Sareen, D., O’Rourke, J.G., Meera, P., Muhammad, A.K., Grant,
S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L.,
Sahabian, A., et al. (2013) Targeting RNA foci in iPSC-derived
motor neurons from ALS patients with a C9ORF72 repeat ex-
pansion. Sci. Transl. Med., 5, 208ra149.
28. Haeusler, A.R., Donnelly, C.J., Periz, G., Simko, E.A., Shaw,
P.G., Kim, M.S., Maragakis, N.J., Troncoso, J.C., Pandey, A.,
Sattler, R., et al. (2014) C9orf72 nucleotide repeat structures
initiate molecular cascades of disease. Nature, 507, 195–200.
29. Xu, Z., Poidevin, M., Li, X., Li, Y., Shu, L., Nelson, D.L., Li, H.,
Hales, C.M., Gearing, M., Wingo, T.S., et al. (2013) Expanded
GGGGCC repeat RNA associated with amyotrophic lateral
sclerosis and frontotemporal dementia causes neurodegen-
eration. Proc. Natl. Acad. Sci. USA, 110, 7778–7783.
30. Cooper-Knock, J., Bury, J.J., Heath, P.R., Wyles, M.,
Higginbottom, A., Gelsthorpe, C., Highley, J.R., Hautbergue,
G., Rattray, M., Kirby, J., et al. (2015) C9ORF72 GGGGCC ex-
panded repeats produce splicing dysregulation which cor-
relates with disease severity in amyotrophic lateral
sclerosis. PLoS One, 10, e0127376.
31. Prudencio, M., Belzil, V.V., Batra, R., Ross, C.A., Gendron, T.F.,
Pregent, L.J., Murray, M.E., Overstreet, K.K., Piazza-Johnston,
A.E., Desaro, P., et al. (2015) Distinct brain transcriptome pro-
files in C9orf72-associated and sporadic ALS. Nat. Neurosci.,
18, 1175–1182.
32. Mori, K., Weng, S.M., Arzberger, T., May, S., Rentzsch, K.,
Kremmer, E., Schmid, B., Kretzschmar, H.A., Cruts, M., Van
1143Human Molecular Genetics, 2017, Vol. 26, No. 6 |
Broeckhoven, C., et al. (2013) The C9orf72 GGGGCC repeat is
translated into aggregating dipeptide-repeat proteins in
FTLD/ALS. Science, 339, 1335–1338.
33. Ash, P.E.A., Bieniek, K.F., Gendron, T.F., Caulfield, T., Lin,
W.L., DeJesus-Hernandez, M., van Blitterswijk, M.M.,
Jansen-West, K., Paul, J.W. III., Rademakers, R., et al. (2013)
Unconventional translation of C9ORF72 GGGGCC expansion
generates insoluble polypeptides specific to c9FTD/ALS.
Neuron, 77, 639–646.
34. Mori, K., Arzberger, T., Gr€asser, F.A., Gijselinck, I., May, S.,
Rentzsch, K., Weng, S.M., Schludi, M.H., van der Zee, J., Cruts,
M., et al. (2013) Bidirectional transcripts of the expanded
C9orf72 hexanucleotide repeat are translated into aggregat-
ing dipeptide repeat proteins. Acta Neuropathol., 126,
881–893.
35. Zu, T., Liu, Y., Ba~nez-Coronel, M., Reid, T., Pletnikova, O.,
Lewis, J., Miller, T.M., Harms, M.B., Falchook, A.E.,
Subramony, S.H., et al. (2013) RAN proteins and RNA foci
from antisense transcripts in C9ORF72 ALS and frontotem-
poral dementia. Proc. Natl. Acad. Sci. USA, 110, E4968–E4977.
36. Kwon, I., Xiang, S., Kato, M., Wu, L., Theodoropoulos, P.,
Wang, T., Kim, J., Yun, J., Xie, Y. and McKnight, S.L. (2014)
Poly-dipeptides encoded by the C9orf72 repeats bind nucle-
oli, impede RNA biogenesis, and kill cells. Science, 345,
1139–1145.
37. Tao, Z., Wang, H., Xia, Q., Li, K., Jiang, X., Xu, G., Wang, G. and
Ying, Z. (2015) Nucleolar stress and impaired stress granule
formation contribute to C9orf72 RAN translation-induced
cytotoxicity. Hum. Mol. Genet., 24, 2426–2441.
38. Wen, X., Tan, W., Westergard, T., Krishnamurthy, K.,
Markandaiah, S.S., Shi, Y., Lin, S., Shneider, N.A., Monaghan,
J., Pandey, U.B., et al. (2014) Antisense proline-arginine RAN
dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear
aggregates that initiate in vitro and in vivo neuronal death.
Neuron, 84, 1213–1225.
39. Yang, D., Abdallah, A., Li, Z., Lu, Y., Almeida, S. and Gao, F.B.
(2015) FTD/ALS-associated poly(GR) protein impairs the
Notch pathway and is recruited by poly(GA) into cytoplasmic
inclusions. Acta Neuropathol., 130, 525–535.
40. May, S., Hornburg, D., Schludi, M.H., Arzberger, T., Rentzsch,
K., Schwenk, B.M., Gr€asser, F.A., Mori, K., Kremmer, E.,
Banzhaf-Strathmann, J., et al. (2014) C9orf72 FTLD/ALS-
associated Gly-Ala dipeptide repeat proteins cause neuronal
toxicity and Unc119 sequestration. Acta Neuropathol., 128,
485–503.
41. Mizielinska, S., Gro¨nke, S., Niccoli, T., Ridler, C.E., Clayton,
E.L., Devoy, A., Moens, T., Norona, F.E., Woollacott, I.O.,
Pietrzyk, J., et al. (2014) C9orf72 repeat expansions cause neu-
rodegeneration in Drosophila through arginine-rich pro-
teins. Science, 345, 1192–1194.
42. Zhang, Y.J., Jansen-West, K., Xu, Y.F., Gendron, T.F., Bieniek,
K.F., Lin, W.L., Sasaguri, H., Caulfield, T., Hubbard, J.,
Daughrity, L., et al. (2014) Aggregation-prone c9FTD/ALS
poly(GA) RAN-translated proteins cause neurotoxicity by
inducing ER stress. Acta Neuropathol., 128, 505–524.
43. Tran, H., Almeida, S., Moore, J., Gendron, T.F., Chalasani, U.,
Lu, Y., Du, X., Nickerson, J.A., Petrucelli, L., Weng, Z., et al.
(2015) Differential toxicity of nuclear RNA foci versus dipep-
tide repeat proteins in a drosophila model of C9ORF72 FTD/
ALS. Neuron, 87, 1207–1214.
44. Cooper-Knock, J., Higginbottom, A., Stopford, M.J., Highley,
J.R., Ince, P.G., Wharton, S.B., Pickering-Brown, S., Kirby, J.,
Hautbergue, G.M. and Shaw, P.J. (2015) Antisense RNA foci in
the motor neurons of C9ORF72-ALS patients are associated
with TDP-43 proteinopathy. Acta Neuropathol., 130, 63–75.
45. Davidson, Y., Robinson, A.C., Liu, X., Wu, D., Troakes, C.,
Rollinson, S., Masuda-Suzukake, M., Suzuki, G., Nonaka, T.,
Shi, J., et al. (2015) Neurodegeneration in frontotemporal
lobar degeneration and motor neurone disease associated
with expansions in C9orf72 is linked to TDP-43 pathology
and not associated with aggregated forms of dipeptide re-
peat proteins. Neuropathol. Appl. Neurobiol., 3, 242–254.
46. Gomez-Deza, J., Lee, Y.B., Troakes, C., Nolan, M., Al-Sarraj, S.,
Gallo, J.M. and Shaw, C.E. (2015) Dipeptide repeat protein in-
clusions are rare in the spinal cord and almost absent from
motor neurons in C9ORF72 mutant amyotrophic lateral
sclerosis and are unlikely to cause their degeneration. Acta
Neuropathol. Commun., 3, 38.
47. Mackenzie, I.R., Arzberger, T., Kremmer, E., Troost, D.,
Lorenzl, S., Mori, K., Weng, S.M., Haass, C., Kretzschmar,
H.A., Edbauer, D., et al. (2013) Dipeptide repeat protein path-
ology in C9ORF72 mutation cases: clinico-pathological cor-
relations. Acta Neuropathol., 126, 859–879.
48. Mackenzie, I.R., Frick, P., Gr€asser, F.A., Gendron, T.F.,
Petrucelli, L., Cashman, N.R., Edbauer, D., Kremmer, E.,
Prudlo, J., Troost, D., et al. (2015) Quantitative analysis and
clinico-pathological correlations of different dipeptide re-
peat protein pathologies in C9ORF72 mutation carriers. Acta
Neuropathol, 130, 845–861.
49. Chew, J., Gendron, T.F., Prudencio, M., Sasaguri, H., Zhang,
Y.J., Castanedes-Casey, M., Lee, C.W., Jansen-West, K., Kurti,
A., Murray, M.E., et al. (2015) Neurodegeneration. C9ORF72 re-
peat expansions in mice cause TDP-43 pathology, neuronal
loss, and behavioral deficits. Science, 348, 1151–1154.
50. O’Rourke, J.G., Bogdanik, L., Muhammad, A.K., Gendron, T.F.,
Kim, K.J., Austin, A., Cady, J., Liu, E.Y., Zarrow, J., Grant, S.,
et al. (2015) C9orf72 BAC transgenic mice display typical
pathologic features of ALS/FTD. Neuron, 88, 892–901.
51. Peters, O.M., Cabrera, G.T., Tran, H., Gendron, T.F., McKeon,
J.E., Metterville, J., Weiss, A., Wightman, N., Salameh, J., Kim,
J., et al. (2015) Human C9ORF72 hexanucleotide expansion re-
produces RNA foci and dipeptide repeat proteins but not
neurodegeneration in BAC transgenic mice. Neuron, 88,
902–909.
52. Jiang, J., Zhu, Q., Gendron, T.F., Saberi, S., McAlonis-Downes,
M., Seelman, A., Stauffer, J.E., Jafar-Nejad, P., Drenner, K.,
Schulte, D., et al. (2016) Gain of toxicity from ALS/FTD-linked
repeat expansions in C9ORF72 is alleviated by antisense
oligonucleotides targeting GGGGCC-containing RNAs.
Neuron, 90, 535–550.
53. Liu, Y., Pattamatta, A., Zu, T., Reid, T., Bardhi, O., Borchelt,
D.R., Yachnis, A.T. and Ranum, L.P. (2016) C9orf72 BAC
mouse model with motor deficits and neurodegenerative
features of ALS/FTD. Neuron, 90, 521–534.
54. Kirby, J., Ning, K., Ferraiuolo, L., Heath, P.R., Ismail, A., Kuo,
S.W., Valori, C.F., Cox, L., Sharrack, B., Wharton, S.B., et al.
(2011) Phosphatase and tensin homologue/protein kinase B
pathway linked to motor neuron survival in human super-
oxide dismutase 1-related amyotrophic lateral sclerosis.
Brain, 134, 506–517.
55. Nalls, M.A., Bras, J., Hernandez, D.G., Keller, M.F., Majounie,
E., Renton, A.E., Saad, M., Jansen, I., Guerreiro, R., Lubbe, S.,
et al. (2015) NeuroX, a fast and efficient genotyping platform
for investigation of neurodegenerative diseases. Neurobiol.
Aging, 36, 1605.e1607–e1612.
1144 | Human Molecular Genetics, 2017, Vol. 26, No. 6
56. Smedley, D., Haider, S., Ballester, B., Holland, R., London, D.,
Thorisson, G. and Kasprzyk, A. (2009) BioMart – biological
queries made easy. BMC Genomics, 10, 22.
57. Milella, M., Falcone, I., Conciatori, F., Cesta Incani, U., Del
Curatolo, A., Inzerilli, N., Nuzzo, C.M., Vaccaro, V., Vari, S.,
Cognetti, F., et al. (2015) PTEN: multiple functions in human
malignant tumors. Front. Oncol., 5, 24.
58. Ning, K., Drepper, C., Valori, C.F., Ahsan, M., Wyles, M.,
Higginbottom, A., Herrmann, T., Shaw, P., Azzouz, M. and
Sendtner, M. (2010) PTEN depletion rescues axonal growth
defect and improves survival in SMN-deficient motor neu-
rons. Hum. Mol. Genet., 19, 3159–3168.
59. Little, D., Valori, C.F., Mutsaers, C.A., Bennett, E.J.,
Wyles, M., Sharrack, B., Shaw, P.J., Gillingwater, T.H.,
Azzouz, M. and Ning, K. (2015) PTEN depletion decreases
disease severity and modestly prolongs survival in a
mouse model of spinal muscular atrophy. Mol. Ther., 23,
270–277.
60. Breitling, R., Armengaud, P., Amtmann, A. and Herzyk, P.
(2004) Rank products: a simple, yet powerful, new method to
detect differentially regulated genes in replicated micro-
array experiments. FEBS Lett., 573, 83–92.
61. Pearson, R.D., Liu, X., Sanguinetti, G., Milo, M., Lawrence,
N.D. and Rattray, M. (2009) puma: a Bioconductor package
for propagating uncertainty in microarray analysis. BMC
Bioinformatics, 10, 211.
62. Rattray, M., Liu, X., Sanguinetti, G., Milo, M. and Lawrence,
N.D. (2006) Propagating uncertainty in microarray data ana-
lysis. Brief Bioinform., 7, 37–47.
63. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.,
Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., et al. (2007)
PLINK: a tool set for whole-genome association and population-
based linkage analyses.Am. J. Hum. Genet., 81, 559–575.
64. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. and Golani, I.
(2001) Controlling the false discovery rate in behavior gen-
etics research. Behav. Brain Res., 125, 279–284.
1145Human Molecular Genetics, 2017, Vol. 26, No. 6 |
